Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biometrics Snags Two Clinical Biomarker Research Contracts

NEW YORK (GenomeWeb News) – Pacific Biometrics said today that it has been awarded two contracts worth a total of $1.6 million from an unnamed company to provide clinical services for use in rheumatoid arthritis drug development programs.
 
The Seattle-based firm said the contracts are part of a series of four contracts related to a global development program. PBI will offer testing for a panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support its partner’s phase III clinical program.
 
PBI CEO Ron Helm said the agreements should “have a meaningful impact” on the company’s financials in 2009, 2010, and in 2011.
 
Helm also said that the drug in question “may have applicability to a broader range of inflammatory diseases” beyond rheumatoid arthritis.
 
Further financial terms of the agreements were not released.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.